Form 4: Pliant Therapeutics Director Thomas McCourt Acquires 26,764 Shares Via Option Grant

Director Thomas McCourt acquired 26,764 shares of Pliant Therapeutics via an option grant on June 13, 2024.

Summary

• On June 13, 2024, Thomas A. McCourt, a director of Pliant Therapeutics, Inc. (PLRX), acquired 26,764 shares of common stock through an option grant.
• The exercise price of the option is $13.06 per share.
• The options vest quarterly, with 25% vesting on the first day of each calendar quarter for three quarters following the grant date.
• The remaining 25% vests on the earlier of the one-year anniversary of the grant date (June 13, 2024) or the next annual meeting of stockholders, contingent upon continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, suggesting confidence. However, it's a routine filing and doesn't contain groundbreaking news.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a continued commitment from the director to the company.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock. This filing indicates a director's acquisition of shares, which is generally viewed positively by investors.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates